Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
parp4 siRNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at San Antonio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
parp4 siRNA nanoparticles are preclinical-stage therapeutic candidates developed by researchers at the University of Texas Health Science Center at San Antonio. These nanoparticles consist of small interfering RNA (siRNA) designed to silence poly(ADP-ribose) polymerase 4 (PARP4), chemically conjugated and encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles. PARP4 acts as a co-regulator of the estrogen receptor (ER), and its overexpression is associated with hormone-dependent breast cancer progression, metastasis, and resistance to endocrine therapies. By knocking down PARP4 expression, these nanoparticles aim to inhibit cell cycle progression, reduce local aromatase activity, suppress metastatic potential, and resensitize hormone-resistant breast cancer cells to endocrine therapies.
- Other names
- PARP4 siRNA PLGA nanoparticlesPARP-4 siRNA PLGA nanoparticlesPARP 4 siRNA PLGA nanoparticlesPLGA-PARP4 siRNA nanoparticlesPLGA-PARP-4 siRNA nanoparticlesPLGA-PARP 4 siRNA nanoparticlesPLGA-siRNA nanoparticles of PARP4
Beyond the preview
Go deeper on parp4 siRNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on parp4 siRNA nanoparticles.